Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 21;23(1):332.
doi: 10.1186/s12883-023-03375-4.

Clinical characteristics and prognosis of temporary miller fisher syndrome following COVID-19 vaccination: a systematic review of case studies

Dorsa Alijanzadeh  1   2   3 , Afsaneh Soltani  2   3 , Fatemeh Afra  2   3   4 , Fardis Salmanpour  2   3   5 , Amir Hossein Loghman  2   3   6 , Noosha Samieefar  2   3 , Nima Rezaei  7   8   9
Affiliations

Clinical characteristics and prognosis of temporary miller fisher syndrome following COVID-19 vaccination: a systematic review of case studies

Dorsa Alijanzadeh et al. BMC Neurol. .

Abstract

Background: Miller Fisher syndrome (MFS) is a subtype of Guillain-Barré syndrome (GBS) which is characterized by the three components of ophthalmoplegia, ataxia, and areflexia. Some studies reported MFS as an adverse effect of the COVID-19 vaccination. We aimed to have a detailed evaluation on demographic, clinical, and para-clinical characteristics of subjects with MFS after receiving COVID-19 vaccines.

Materials and methods: A thorough search strategy was designed, and PubMed, Web of Science, and Embase were searched to find relevant articles. Each screening step was done by twice, and in case of disagreement, another author was consulted. Data on different characteristics of the patients and types of the vaccines were extracted. The risk of bias of the studies was assessed using Joanna Briggs Institute (JBI) tools.

Results: In this study, 15 patients were identified from 15 case studies. The median age of the patients was 64, ranging from 24 to 84 years. Ten patients (66.6%) were men and Pfizer made up 46.7% of the injected vaccines. The median time from vaccination to symptoms onset was 14 days and varied from 7 to 35 days. Furthermore,14 patients had ocular signs, and 78.3% (11/14) of ocular manifestations were bilateral. Among neurological conditions, other than MFS triad, facial weakness or facial nerve palsy was the most frequently reported side effect that was in seven (46.7%) subjects. Intravenous immunoglobulin (IVIg) was the most frequently used treatment (13/15, 86.7%). Six patients received 0.4 g/kg and the four had 2 g/kg. Patients stayed at the hospital from five to 51 days. No fatal outcomes were reported. Finally, 40.0% (4/15) of patients completely recovered, and the rest experienced improvement.

Conclusion: MFS after COVID-19 immunization has favorable outcomes and good prognosis. However, long interval from disease presentation to treatment in some studies indicates that more attention should be paid to MFS as the adverse effect of the vaccination. Due to the challenging diagnosis, MFS must be considered in list of the differential diagnosis in patients with a history of recent COVID-19 vaccination and any of the ocular complaints, ataxia, or loss of reflexes, specially for male patients in their 60s and 70s.

Keywords: Areflexia; Ataxia; COVID-19 vaccine; Guillain– Barré syndrome; MFS; Miller-Fisher syndrome; Ophthalmoplegia; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Flow chart of included studies with detailed exclusion reasons (PRISMA Flow Diagram)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia) N Engl J Med. 1956;255(2):57–65. doi: 10.1056/NEJM195607122550201. - DOI - PubMed
    1. Berlit P, Rakicky J. The Miller Fisher syndrome. Review of the literature. J Clin Neuro-ophthalmol. 1992;12(1):57–63. - PubMed
    1. Snyder LA, Rismondo V, Miller NR. The Fisher variant of Guillain-Barré syndrome (Fisher syndrome) J Neuroophthalmol. 2009;29(4):312–324. doi: 10.1097/WNO.0b013e3181c2514b. - DOI - PubMed
    1. Koga M, Yuki N, Tai T, Hirata K. Miller Fisher syndrome and Haemophilus influenzae infection. Neurology. 2001;57(4):686–691. doi: 10.1212/WNL.57.4.686. - DOI - PubMed
    1. Thaler A. Miller Fisher syndrome in a 66-year-old female after flu and pneumovax vaccinations. J Am Med Dir Assoc. 2008;9(4):283–284. doi: 10.1016/j.jamda.2008.01.013. - DOI - PubMed

Publication types

Substances